Broad-spectrum inflammasome inhibition by thiomuscimol
Related Experiment Video
Updated: Jun 7, 2025
Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
Marisa J Anderson1, Andreas B den Hartigh1, Wendy P Loomis1
1Department of Laboratory Medicine and Pathology, University of Washington, Seattle, Washington, USA.
Abstract:
Inflammasome formation, arising from pathogen or internal activating signals, is a key step in canonical pyroptosis, a gasdermin-mediated inflammatory cell death. Inhibition of pyroptosis has great clinical relevance due to its involvement in many different disease states. Current inhibitors of pyroptosis either only inhibit the final lytic step, which still allows inflammatory signal release, or only inhibit a single inflammasome, which does not account for inherent redundancy in activation of other inflammatory pathways. Here, we show that thiomuscimol, a structural analog of the lysis inhibitor muscimol, exhibits unique inhibitory activity upstream of plasma membrane rupture. We find that thiomuscimol inhibits inflammasome formation, as well as downstream caspase-1 activation, initiated by multiple pyroptotic signals, regardless of whether NLR recruitment of caspase-1 to the inflammasome relies on the ASC adapter protein. The ability of thiomuscimol to block multiple different inflammasomes opens the door for development of therapeutics with increased applications to broadly inhibit pyroptosis in multiple pathological settings.
Insights
Thiomuscimol inhibits inflammasome formation and caspase-1 activation, key steps in pyroptosis (inflammatory cell death). This novel inhibitor blocks multiple inflammasomes, offering broad therapeutic potential for inflammatory diseases.
Area of Science:
- Cellular Biology
- Immunology
- Pharmacology
Background:
- Pyroptosis is a gasdermin-mediated inflammatory cell death pathway crucial in disease.
- Current pyroptosis inhibitors have limitations, either allowing inflammatory signal release or targeting only single inflammasomes.
- Targeting pyroptosis is clinically relevant for numerous inflammatory conditions.
Purpose of the Study:
- To identify novel inhibitors of inflammasome formation upstream of plasma membrane rupture.
- To evaluate the efficacy of thiomuscimol, a muscimol analog, in inhibiting pyroptosis.
- To explore the potential of broad-spectrum inflammasome inhibition for therapeutic applications.
Main Methods:
- Investigated thiomuscimol's inhibitory activity on inflammasome formation and caspase-1 activation.
- Assessed inhibition across various pyroptotic signaling pathways, including ASC-dependent and -independent inflammasomes.
- Utilized thiomuscimol as a structural analog of the lysis inhibitor muscimol.
Main Results:
- Thiomuscimol demonstrated inhibitory activity upstream of plasma membrane rupture.
- It effectively inhibited inflammasome formation and downstream caspase-1 activation.
- Thiomuscimol blocked multiple inflammasomes, irrespective of ASC adapter protein involvement.
Conclusions:
- Thiomuscimol represents a novel therapeutic strategy for inhibiting pyroptosis.
- Its ability to block diverse inflammasomes offers broad applicability in treating inflammatory diseases.
- This discovery paves the way for developing new pyroptosis inhibitors with wider therapeutic potential.
More Related Videos
Related Concept Videos
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
01:25Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
01:20Antiasthma Drugs: Muscarinic Receptor Antagonists
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids